Differentiation therapies using All-trans-retinoic acid (ATRA) are highly efficient at treating Acute Promyelocytic Leukemia (APL), a minor subtype of Acute Myeloid Leukemias (AML). However, their efficacy, if any, is very limited in the case of non-APL AMLs. We report here that the inhibition of SUMOylation, a post-translational modification related to ubiquitinylation, restores the pro-differentiation and anti-proliferative activities of retinoids in non-APL AMLs. Controlled inhibition of SUMOylation with pharmacological inhibitors (2-D08 or anacardic acid), or via overexpression of SENP desumoylases, strongly enhances the ATRA-induced expression of key genes involved in differentiation, proliferation and apoptosis in non-APL AML cells. This activates ATRA-induced terminal myeloid differentiation and reduces cell proliferation and viability, including in AML cells resistant to chemotherapeutic drugs. Conversely, enhancement of SUMOylation by overexpressing the SUMO-conjugating enzyme Ubc9 dampens the expression of ATRA-responsive genes and prevents differentiation. Thus, inhibition of the SUMO pathway is a promising strategy to sensitize non-APL AML patients to retinoids and improve the treatment of this poor prognosis cancer, which has not significantly changed over the past 40 years.
Introduction
Acute Myeloid Leukemias (AML) are a heterogeneous group of severe hematological malignancies. They arise through the acquisition of oncogenic mutations by hematopoietic stem-or progenitor cells. Instead of differentiating into normal blood constituents, leukemic cells are blocked at intermediate differentiation stages, proliferate and infiltrate the bone marrow, leading to the disease (1) . Except for the Acute Promyelocytic Leukemia (APL) subtype, the standard treatment of AMLs has little changed over the past 40 years. It generally consists of intensive chemotherapy composed of one anthracyclin (daunorubicin or idarubicin) and the nucleoside analog cytarabine (Ara-C). However, relapses are frequent (40 to 70% of patients, depending on prognosis factors) (2) and the overall survival very low, making novel treatments urgently needed.
Differentiation therapies have appeared as a powerful strategy for AML treatment. They rely on the idea that restoration of differentiation is associated with cell division arrest, followed by death due to the naturally limited lifespan of differentiated cells. This approach has proved particularly efficient at curing APL(3), a minor AML subtype characterized by the expression of oncogenic fusion proteins engaging the retinoic acid receptor α (RARα), which belongs to the nuclear receptor family. APL therapy is based on pharmacological doses of its natural ligand, all-trans-retinoic acid (ATRA) used in combination with Arsenic Trioxide (4) . ATRA leads to the degradation of the oncogenic RARα fusion protein and activates wild-type RARα. This activates a specific transcriptional program, which drives differentiation, cell cycle arrest and death of the leukemic cells (5, 6) . ATRA also induces to various degrees the in vitro differentiation of certain non-APL AML cell lines and primary cells from a substantial number of non-APL AMLs (6) . This includes AMLs mutated in the NPM1- (7) , IDH1/IDH2- (8) or FLT3-ITD genes (9) or overexpressing the transcription factor EVI-1 (10) . However, the clinical trials conducted so far have failed to prove a significant efficacy of ATRA on non-APL AML patients, including in combination with other drugs (11) . This lack of effect has been attributed to the inability of ATRA to induce the expression of critical genes involved in differentiation, cell cycle arrest or apoptosis (6, 12) . Interestingly, targeting epigenetic enzymes has recently appeared promising to restore the ability of ATRA to activate RARα target genes and potentiate ATRA-induced differentiation of non-APL AMLs (6, 11, 12) . For instance, inhibition of histone deacetylases (HDAC) with valproic acid was shown to favor ATRAinduced differentiation of non-APL AML cells (13) . However, the clinical trials conducted so far showed only limited effects in a subset of the patients treated with the combination of ATRA and valproic acid (14) (15) (16) . More recently, inhibition of the histone demethylase LSD1/KDM1A was also shown to strongly sensitize AML cells to ATRA in preclinical models via transcriptional reprogramming (17) . Phase I/II trials are ongoing to determine the clinical efficacy of the combination between ATRA and LSD1 inhibitors.
SUMO is a group of 3 (SUMO-1 to -3) ubiquitin-related polypeptidic post-translational modifiers covalently and reversibly conjugated to numerous intracellular proteins to regulate their function and fate (18) . Its conjugation involves a unique E1 SUMO-activating enzyme, a unique E2-conjugating enzyme (Ubc9) and several E3 SUMO ligases (19) . Deconjugation is ensured by deSUMOylases, in particular of the SENP family. Increasing evidence links deregulation of the SUMO pathway to cancer (20, 21) , including in hematological malignancies such as lymphomas (22) and multiple myeloma (23) . In the case of AMLs, the SUMO pathway is essential for efficient differentiation therapy of APLs by an ATRA + arsenic trioxide combination treatment. Arsenic trioxide induces the rapid SUMOylation of the PML-RARα oncoprotein, which initiates its elimination by the ubiquitin/proteasome system (24) (25) (26) . In addition, we have shown that inhibition of the SUMO pathway by genotoxics-induced reactive oxygen species (ROS) is essential for fast and efficient cell death of chemosensitive non-APL AML cells subjected to antracyclins or Ara-C treatment (27) .
SUMO is increasingly viewed as an epigenetic mark highly enriched at gene promoters (28) (29) (30) . It regulates gene expression via modification of numerous transcription factors/coregulators, histone-modifying enzymes, RNA polymerases and even histones (31, 32) .
Although sometimes associated with transcriptional activation (33) , SUMOylation at gene promoters is mostly known to limit or repress transcription (28, 32, (34) (35) (36) (37) . In particular SUMOylation facilitates the recruitment of SUMO-interacting motifs (SIM)-containing corepressors on promoters (31, 38, 39) . We show here that SUMOylation takes part in the epigenetic silencing of ATRA-responsive genes in non-APL AMLs. Its inhibition strongly activates the pro-differentiating and anti-leukemic effect of ATRA in these cancers, which opens new perspectives in the treatment of this poor prognosis cancer.
Methods

Cell lines and primary AML patient cell culture:
U937, HL60, THP1, MOLM14 cells (obtained from DSMZ, Germany) were cultured in RPMI containing 10% fetal bovine serum (FBS) and streptomycin/penicillin at 37°C in the presence of 5% CO 2 . U937 cells resistant to Ara-C were generated by culturing the cells for 2 months in the presence of increasing Ara-C concentration (up to 0.1 µM). Fresh bone marrow aspirates were collected after obtaining informed consents from patients (Ethical Committee « Sud Méditerranée 1 », ref 2013-A00260-45, HemoDiag collection). Fresh leukocytes were purified using density-based centrifugation using Histopaque 1077 from SIGMA and resuspended at a concentration of 10 6 /ml in IMDM (SIGMA) complemented with 1.5 mg/ml bovine serum albumin, 4.4 µg/ml insulin (SIGMA), 60 µg/ml transferrin (SIGMA), 5% streptomycin + penicillin, 5% FBS, 5 µM ß-mercaptoethanol, 1 mM pyruvate, 1x MEM nonessential amino acids (Life Technologies), 10 ng/ml IL-3 (PeproTech), 40 ng/ml SCF (PeproTech), and 10 ng/ml TPO (PeproTech).
Pharmacological inhibitors, reagents, and antibodies:
All-trans-retinoic acid (ATRA) was from Sigma. It was resuspended at a 100 mM concentration in DMSO and stored at -20°C for a maximum of 2 weeks. Anacardic acid was from Santa Cruz Biotechnologies and 2-D08 from Merck-Millipore. Anti-SUMO-1-(21C7) and SUMO-2 (8A2) hybridomas were from the Developmental Studies Hybridoma Bank. The anti H3K4Me 3 antiserum was from Abcam.
Flow cytometry:
Cells were washed in PBS containing 2% FBS and incubated at 4°C for 30 minutes in the presence of the following fluorophore-conjugated antibodies: CD45-Pacific Blue (A74763;
Beckman Coulter), CD14-PE (130-091-242; Miltenyi), CD15-PE-Vio770 (130-100-425; Miltenyi), CD11b-APC (130-109-286; Miltenyi). Matched isotype controls were used for each treatment condition. After washing, cells were analyzed using the LSR Fortessa flow cytometer (Becton Dickinson) and the FacsDiva software. Data were analyzed using the FlowJo software (version 10). For patient samples, MFIs for each differentiation marker were measured on leukemic cells previously selected using CD45/SSC gating (40) . MFIs from isotype controls were subtracted from each treatment condition.
Microscopic analyses:
Cell lines or patient samples were cytospun on microscope slides (1500 rpm for 5 min), dried for 5 min and stained, first with May-Grunwald-(5 min) and, then, Giemsa (1/10 dilution, 15 min) stain (MGG staining). Microscopic examinations were performed using the AxioImager Z2 microscope (Zeiss).
Cell viability, cell cycle and proliferation assay:
For proliferation assays on cell lines, cells were seeded at a concentration of 3x10 5 /ml and viable cells were counted at regular intervals using the Trypan-blue exclusion method with an EVE automatic cell counter. Cell cycle distribution was analyzed by Propidium Iodine (PI) staining. Cells were washed once with PBS and fixed with cold 70% ethanol for 10 min and washed once with PBS. 100 µg/mL RNAase A (Sigma) was then added for 10 min at room temperature. Cells were washed with PBS and stained with 50 µg/mL PI (Sigma) for 10 min at room temperature. Cells were then washed once with PBS and analyzed by flow cytometry.
For patient cells, equal numbers of CountBright TM absolute counting beads (C36950; Life
Technologies) were added to each sample. Viable cells were selected using the CD45/SSC gating and their number was normalized to the number of beads counted in the same sample.
Retroviral Infections:
Retroviral constructs expressing either Ubc9, SENP2 or SENP5 were constructed by inserting human cDNA using the Gateway cloning technology (ThermoFisher Scientific) into the pMIG retroviral vector (41) , which also coexpress EGFP from the same polycistronic mRNA.
Retroviruses were produced by cotransfection of these constructs with gag-pol-and VSVG expression vectors into HEK293T cells using Lipofectamine-2000 (Invitrogen). Viral supernatants were collected 48hr later, 0.45 µm-filtered and directly used to infect AML cell lines. Only EGFP-positive cells were considered in flow cytometry analyses. Where indicated, the EGFP-positive cells were sorted using the FACS-Aria cell sorter (Beckton Dickinson)
RT-qPCR assays:
Total mRNA was purified using the GenElute Mammalian Total RNA kit (Sigma). After DNase I treatment, 1 µg of total RNA was used for cDNA synthesis using the Maxima First Strand cDNA kit (ThermoFisher Scientific). qPCR assays were conducted using Taq platinium (Invitrogen) and the LightCycler 480 device (Roche) with specific DNA primers (see primer table). Data were normalized to the housekeeping TBP mRNA levels.
Chromatin immunoprecipitation assays (ChIPs):
30.10 6 cells were cross-linked with 1% paraformaldehyde for 8 minutes. Paraformaldehyde was then neutralized with 125 mM glycine for 10 minutes. Cross-linked cells were washed with cold PBS, resuspended in a cell lysis buffer (5 mM PIPES pH7.5, 85 mM KCl, 0.5% NP40, 20 mM N-ethyl maleimide, 1 µg/mL of aprotinin, pepstatin, leupeptin, 1 mM AEBSF) and incubated at 4°C for 10 minutes with rotation. Nuclei were centrifuged (5,000 rpm for 10 minutes at 4°C) and resuspended in a nucleus lysis buffer (50 mM Tris-HCl pH 7.5, 1% SDS, 10 mM EDTA, 20 mM N-ethyl maleimide, 1 µg/mL of aprotinin, pepstatin, leupeptin, 1 mM AEBSF) and incubated at 4°C for 2.5 hours. Lysates were then sonicated for 30 cycles of 30 seconds each at 4°C using the Bioruptor Pico (Diagenode) under standard conditions. After sonication, samples were centrifuged (13,000 rpm for 10 minutes at 4°C) and the supernatants were diluted 10-fold in the immunoprecipitation buffer (1.1% Triton X100, 50 mM Tris-HCl pH 7.5, 167 mM NaCl, 5 mM N-ethyl maleimide, 1 mM EDTA, 0.01% SDS, 1 µg/mL of aprotinin, pepstatin, leupeptin, 1 mM AEBSF) with 2 µg of antibodies and Dynabeads Protein G (ThermoFisher Scientific). Immunoprecipitations were performed overnight at 4°C. Beads were then washed in low salt buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 1% Triton X100, 0.1% SDS, 1 mM EDTA), high salt buffer (50 mM Tris-HCl pH7.5, 500 mM NaCl, 1% Triton X100, 0.1% SDS, 1 mM EDTA), LiCl salt (20 mM Tris-HCl pH7.5, 250 mM LiCl, 1% NP40, 1% deoxycholic acid, 1 mM EDTA) and TE buffer (10 mM Tris-HCl pH7.5, 0.2% Tween20, 1 mM EDTA). Elution was done in 200 µL of 100 mM NaHCO 3 , 1% SDS.
Chromatin crosslinking was reversed by overnight incubation at 65°C with 280 mM NaCl followed and 2h at 45°C with 35 mM Tris-HCl pH6.8, 9 mM EDTA, 88 µg/mL RNAse, 88 µg/mL Proteinase K. Immunoprecipitated DNAs were purified using the Nucleospin Gel and PCR Cleanup kit (Macherey-Nagel). Immunoprecipitated DNA and DNA inputs purified from samples before immunoprecipitation were subjected to PCR analysis using the Roche LightCycler 480 device using appropriate primers (see primer table) Gene name Use Forward primer Reverse primer Altogether, these data suggest that the SUMO pathway limits the differentiating effects of ATRA on various non-APL AML cell lines and that its inhibition could favor their ATRAinduced differentiation, including in the case of resistance to a chemotherapeutics used in AML treatment.
SUMOylation limits ATRA-induced expression of myeloid differentiation-associated genes
We then wondered if the repressive action of SUMOylation on ATRA-induced differentiation could be linked to its well-characterized ability to repress/limit gene expression (38) .
Inhibition of SUMOylation with 2-D08 was sufficient on its own to increase the expression of various ATRA-responsive genes associated with myeloid differentiation, such as RARA, CEBPA, TNFSF10, ITGAX, ITGAM and IL1B ( Figure 3A ). This suggests that inhibition of SUMOylation might prime differentiation by increasing the basal expression of master genes involved in myeloid differentiation. In addition to basal expression, 2-D08 also increased the ATRA-induced expression of most of those genes ( Figure 3A ). To determine if SUMOylation controls the expression of these genes at the level of chromatin, we assayed the active transcription-associated histone mark H3K4me 3 on their promoters. An increase of this mark correlated with the level of expression of RARA, ITGAX, CEBPA and TNFSF10 mRNAs ( Figure 3B ), suggesting that SUMOylation represses ATRA-responsive genes induction at the level of chromatin.
Inhibition of SUMOylation potentiates the anti-leukemic effects of ATRA.
Differentiated cells stop proliferating and have a shorter lifespan than undifferentiated cells.
Consistently, ATRA and 2-D08 synergized to block the proliferation of both U937 cells ( Figure 4A ) and their Ara-C resistant variants in vitro ( Figure 4B ). This correlated with an accumulation of cells in G0/G1 ( Figure 4C ) and a strong activation of the CDKN1A gene encoding the CDK inhibitor p21CIP1 ( Figure 4D ). This suggests that inhibition of SUMOylation increases the anti-proliferative effects of ATRA in vitro by inducing a cell cycle arrest. To determine if this would also be the case in vivo, we treated immunodeficient mice subcutaneously xenografted with U937 cells with ATRA, 2-D08 or ATRA+2-D08 after engraftment. Only the combination of ATRA and 2-D08 induced a significant reduction in tumor growth whereas ATRA and 2-D08 alone showed slight, if any, effects ( Figure 4E-F) .
Thus, the combination of ATRA with an inhibitor of SUMOylation can, not only promote non-APL AML cell differentiation, but also exert anti-proliferative effects both in vitro and in vivo.
Genetic modulation of the SUMO pathway affects ATRA-induced differentiation of non-APL AML cells.
To rule out possible off-target effects of 2-D08 and anacardic acid, we resorted to the genetic manipulation of the SUMO pathway to confirm the role of SUMOylation on ATRA-induced differentiation in non-APL AMLs. In a first step, we induced a hypo-SUMOylated state in U937 cells by overexpressing either the SENP-2-or the SENP-5 desumoylase. This led to a significant increase in their ATRA-induced differentiation, as assayed by the expression of CD11b ( Figure 5A ). Interestingly, this correlated with a reduction in their proliferation ( Figure 5B ). Overexpression of SENP-2 also increased ATRA-induced differentiation of HL-60 cells ( Figure 5C ) and was associated with stronger expression of various ATRAresponsive genes (RARA, CEBPA, ITGAM and IL1B; Figure 5D ). Interestingly, although SENP-2-expressing HL60 cells did not appear more differentiated than control cells in the absence of ATRA, they showed higher basal expression of these genes. This further supports the idea that inhibition of SUMOylation could prime AML cells for differentiation. In a second step, we increased SUMOylation in THP1 cells via overexpression of the SUMO E2conjugating enzyme Ubc9. This led to a massive decrease in ATRA-induced differentiation, as assayed by CD14 expression ( Figure 6A ) and morphological changes (appearance of pseudopods, cytosolic vesicles and granules) ( Figure 6B ). Moreover, Ubc9 overexpression strongly decreased basal expression and/or induction of genes involved in myeloid differentiation by ATRA ( Figure 6C ). Altogether, this confirms the repressive role of the SUMO pathway on ATRA-induced differentiation of non-APL AMLs.
Inhibition of SUMOylation potentiates the pro-differentiating and anti-proliferative activities of ATRA on primary AML cells.
We finally asked whether inhibiting SUMOylation could also favor the in vitro differentiation of primary AML cells using bone marrow aspirates from AML patients at diagnosis. ATRA alone did not significantly induce their differentiation, as assayed by CD15 expression. 2-D08
and AA alone showed a slight pro-differentiating trend with, however, no statistical significance. In contrast, combining either of them with ATRA significantly increased CD15 expression compared to cells treated with ATRA alone ( Figure 7A ). Some patient cells were more sensitive to the differentiating effects of the ATRA+SUMOylation inhibitor combination than others, but they neither belonged to a unique FAB subtype nor shared cytogenetic/genetic abnormalities tested at diagnosis. Inhibitors of SUMOylation also increased the number of cells showing morphological changes typical of differentiation, such as nuclear lobulation, cytosol enlargement or appearance of cytosolic granules on cells from the two patients tested ( Figure 7B and Supplementary Figure 2) . Interestingly, 2-D08 and AA also potentiated ATRA-induced differentiation of primary cells from 1 patient not responsive to induction chemotherapy (AML1), as well as from 2 (AML2 and -4) out of 3 patients at relapse ( Figure 7C ). Importantly, both inhibitors increased the anti-leukemic activity of ATRA on the primary AML cells ( Figure 7D ). Altogether, these data confirm that SUMOylation inhibitors potentiate ATRA-induced differentiation of different non-APL AML subtypes and indicated novel therapeutic approach, including in the case of conventional chemotherapy failure. More than 6000 SUMOylated proteins have been identified so far (18, 45) . Among them are many transcription factors and co-regulators, some of which play key roles in myeloid differentiation. This is the case of CEBPα and CEBPε. Their SUMOylation was shown to repress and activate their transactivation capacities, respectively (46, 47) . The ATRA-receptor RARα also undergoes dynamic SUMOylation/deSUMOylation cycles essential for its ATRAinduced activation (48, 49) . The SUMOylation of these transcription factors could participate in the silencing of ATRA-responsive genes that we have uncovered in non-APL AMLs.
Discussion
However, transcriptional repression of differentiation-associated genes by the SUMO pathway might not just result from the SUMOylation of single transcription factors, but from coordinated SUMOylation of multiple proteins bound to regulatory elements in the promoter/enhancers of these genes. Supporting the latter possibility, the concept of "group SUMOylation", which has originally emerged from DNA repair regulation studies (50) However, its pharmacological properties and bioavailability have not been tested in vivo.
Should they be better than those of 2-D08 and AA, this would permit an in-depth assessment of the therapeutic benefit of the ATRA+SUMOylation inhibitor association and, in fine, clinical use. In conclusion, our work suggests that targeting the SUMO pathway is a promising strategy to enhance the clinical efficacy of ATRA in non APL-AML and improve the treatment of this poor prognosis cancer. Four days after injection, mice were treated peritumorally with 2-D08 (10 mg/kg) and/or ATRA (2.5 mg/kg) every 2 days for 10 days. Tumor volumes were measured every 2 days and are presented for all mice at day 8 on (F). Tumors smaller than 30 mm 3 before the beginning of the treatment were excluded from the analysis. The p values indicated in (E) were calculated between the DMSO and the ATRA+2-D08 conditions. Transduced cells were treated, or not, with ATRA (1 µM) for 9 days. Note that the ATRA concentration was twice that used in Figure 2A 
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